Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3696-3707

  Shing, Danielle C ^a   Trubia, Maurizio ^b   Marchesi, Francesco ^c   Radaelli, Enrico ^c   Belloni, Elena ^b   Tapinassi, Cinzia ^b   Scanziani, Eugenio ^c   Mecucci, Cristina ^d   Crescenzi, Barbara ^d   Lahortiga, Idoya ^e   Odero, Maria D ^e   Zardo, Giuseppe ^f   Gruszka, Alicja ^a   Minucci, Saverio ^a   Di Fiore, Pier Paolo ^b   Pelicci, Pier Giuseppe ^a,c,g  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF NAVARRA   (Spain)

^f San Raffaele Biomedical Park Foundation   (Italy)

^g Department of Experimental Oncology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; NUCLEOPHOSMIN; PROTEIN P53; PROTEIN PRDM16; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL MODEL; ARTICLE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; KARYOTYPE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANIMALS; BONE MARROW; CELL AGING; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36849080028     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32390     Document Type: Article

References (47)

1. Passegue, E., Jamieson, C.H., Ailles, L.E., and Weissman, I.L. 2003. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. U. S. A. 100(Suppl. 1):11842-11849.
2. Hoffman, R., et al. 2000. Hematology: basic principles and practice. Churchill Livingstone. Philadelphia, Pennsylvania, USA. 2896 pp.
3. Look, A.T. 1997. Oncogenic transcription factors in the human acute leukemias. Science. 278:1059-1064.
4. Falini, B., et al. 2005. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352:254-266.
5. Minucci, S., et al. 2002. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood. 100:2989-2995.
6. Higuchi, M., et al. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 1:63-74.
7. Wattel, E., et al. 1994. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84:3148-3157.
8. Schnittger, S., et al. 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 100:59-66.
9. Bacher, U., Haferlach, T., Schoch, C., Kern, W., and Schnittger, S. 2006. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 107:3847-3853.
10. Shimizu, S., et al. 2000. Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21). Genes Chromosomes Cancer. 27:229-238.
11. Mochizuki, N., et al. 2000. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood. 96:3209-3214.
12. Sakai, I., et al. 2005. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes Chromosomes Cancer. 44:265-270.
13. Stevens-Kroef, M.J., et al. 2006. Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML. Leukemia. 20:1187-1189.
14. Hazourli, S., et al. 2006. Overexpression of PRDM16 in the presence and absence of the RUNX1/ PRDM16 fusion gene in myeloid leukemias. Genes Chromosomes Cancer. 45:1072-1076.
15. Bloomfield, C.D., Garson, O.M., Volin, L., Knuutila, S., and de la Chapelle, A. 1985. t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic-clinicopathologic association. Blood. 66:1409-1413.
16. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., Lowenberg, B., and Delwel, R. 2003. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia. Exp. Hematol. 31:1066-1072.
17. Nishikata, I., et al. 2003. A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood. 102:3323-3332.
18. Jiang, G.L., and Huang, S. 2000. The yin-yang of PR-domain family genes in tumorigenesis. Histol. Histopathol. 15:109-117.
19. Nucifora, G., et al. 1994. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc. Natl. Acad. Sci. U. S. A. 91:4004-4008.
20. Morishita, K., et al. 1992. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc. Natl. Acad. Sci. U. S. A. 89:3937-3941.
21. Xiao, Z., et al. 2006. MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Leuk. Res. 30:332-334.
22. Yoshida, M., et al. 2004. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood. 103:2753-2760.
23. Du, Y., Jenkins, N.A., and Copeland, N.G. 2005. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 106:3932-3939.
24. Sutherland, H.J., Lansdorp, P.M., Henkelman, D.H., Eaves, A.C., and Eaves, C.J. 1990. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc. Natl. Acad. Sci. U. S. A. 87:3584-3588.
25. Ploemacher, R.E., van der Sluijs, J.P., Voerman, J.S., and Brons, N.H. 1989. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood. 74:2755-2763.
26. Kogan, S.C., et al. 2002. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 100:238-245.
27. Harvey, M., McArthur, M.J., Montgomery, C.A., Jr., Bradley, A., and Donehower, L.A. 1993. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7:938-943.
28. Nawa, G., Miyoshi, Y., Yoshikawa, H., Ochi, T., and Nakamura, Y. 1999. Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours. Br. J. Cancer. 80:1185-1189.
29. Hamelin, R., et al. 1994. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 106:42-48.
30. Gentile, M., Bergman Jungestrom, M., Olsen, K.E., Soderkvist, P., and Wingren, S. 1999. p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur. J. Cancer. 35:1202-1207.
31. Kato, S., et al. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U. S. A. 100:8424-8429.
32. Thiede, C., et al. 2006. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 107:4011-4020.
33. Pasqualucci, L., et al. 2006. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood. 108:4146-4155.
34. Dohner, K., et al. 2005. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 106:3740-3746.
35. Colombo, E., et al. 2006. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res. 66:3044-3050.
36. den Besten, W., Kuo, M.L., Williams, R.T., and Sherr, C.J. 2005. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle. 4:1593-1598.
37. Suzuki, T., et al. 2005. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 106:2854-2861.
38. Krivtsov, A.V., et al. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 442:818-822.
39. Huntly, B.J., et al. 2004. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 6:587-596.
40. Cozzio, A., et al. 2003. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17:3029-3035.
41. Alcalay, M., et al. 2005. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 106:899-902.
42. Yuasa, H., et al. 2005. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 24:1976-1987.
43. Vousden, K.H., and Prives, C. 2005. P53 and prognosis: new insights and further complexity. Cell. 120:7-10.
44. Efeyan, A., and Serrano, M. 2007. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle. 6:1006-1010.
45. Belloni, E., et al. 2005. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer. 42:320-325.
46. Zardo, G., et al. 2002. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat. Genet. 32:453-458.
47. Lahortiga, I., et al. 2004. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene. 23:311-316.